BIOMAT Database Logo BIOMAT Database Logo

The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. 2013

Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Advanced Medical Research Institute of Canada; Sudbury, ON Canada.

Hepatitis B (HBV) virus infects the liver, and upon chronic infection, can cause liver cirrhosis and hepatocellular carcinoma. Despite universal vaccination programs against the virus, HBV still affects over 2 billion people worldwide, with over 240 million developing a chronic infection. While current alum-adjuvanted vaccines have shown efficacy in promoting seroprotection in healthy adults, 5-10% of immune-competent populations fail to achieve long-lasting seroprotection from these formulations. Furthermore, a large proportion of immunocompromised patients fail to achieve seroprotective antibody titers after receiving these vaccines. A novel vaccine candidate, HEPLISAV™, uses immunostimulatory sequences (ISS), in its formulation that helps induce a robust humoral and cell mediated immunity against HBV. In Phase III clinical trials, HEPLISAV™ has been shown to elicit seroprotective antibody titers with fewer immunizations. Similar safety profiles are demonstrated when compared with current HBV vaccines. For these reasons, HEPLISAV™ is an attractive vaccine to combat this global disease.

UI MeSH Term Description Entries
D009838 Oligodeoxyribonucleotides A group of deoxyribonucleotides (up to 12) in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties. Oligodeoxynucleotide,Oligodeoxyribonucleotide,Oligodeoxynucleotides
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D017325 Hepatitis B Vaccines Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced. Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B
D017326 Clinical Trials, Phase III as Topic Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries. Clinical Trials, Phase 3 as Topic,Drug Evaluation, FDA Phase 3 as Topic,Drug Evaluation, FDA Phase III as Topic,Evaluation Studies, FDA Phase 3 as Topic,Evaluation Studies, FDA Phase III as Topic
D064420 Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals. Drug-Related Side Effects and Adverse Reaction,Adverse Drug Event,Adverse Drug Reaction,Drug Side Effects,Drug Toxicity,Side Effects of Drugs,Toxicity, Drug,Adverse Drug Events,Adverse Drug Reactions,Drug Event, Adverse,Drug Events, Adverse,Drug Reaction, Adverse,Drug Reactions, Adverse,Drug Related Side Effects and Adverse Reaction,Drug Related Side Effects and Adverse Reactions,Drug Side Effect,Drug Toxicities,Effects, Drug Side,Reactions, Adverse Drug,Side Effect, Drug,Side Effects, Drug,Toxicities, Drug

Related Publications

Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
April 2011, Expert review of vaccines,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.
November 2007, Expert opinion on biological therapy,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant.
June 2021, The Annals of pharmacotherapy,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
March 2012, Vaccine,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
August 2013, Vaccine,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
September 2002, Vaccine,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update.
May 2021, Expert review of vaccines,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Adjuvant synergy in the response to hepatitis B vaccines.
October 2003, Vaccine,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease.
February 2023, Inflammatory bowel diseases,
Nelson F Eng, and Nitin Bhardwaj, and Rebecca Mulligan, and Francisco Diaz-Mitoma
A two-dose hepatitis B vaccine for adults (Heplisav-B).
January 2018, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!